Author/Authors :
Ghaderi، Bayazid نويسنده Department of Internal Medicine, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran , , Amini، Sabrieh نويسنده Department of Biology, College of Science, Islamic Azad University, Sanandaj, IR Iran , , Maroofi، Farzad نويسنده Department of Biology, College of Science, Islamic Azad University, Sanandaj, IR Iran , , Jalali، Chiya نويسنده Department of Biology, College of Science, Islamic Azad University, Sanandaj, IR Iran , , Javanmardi، Mitra نويسنده Department of Biology, College of Science, Islamic Azad University, Sanandaj, IR Iran , , Roshani، Daem نويسنده Department of Epidemiology, Kurdistan University of Medical Sciences, Sanandaj, Iran , , Abdi، Mohammad نويسنده Department of Nursing, School of Nursing and Midwifery,
Kashan University of Medical Sciences, Kashan, IR
Iran ,
Abstract :
Background
B cell chronic lymphocytic leukemia is one of the most frequent hematologic malignancies in the world. Cellular surface CD markers and serum Beta-2-microglobulin may be used as a prognostic tool in CLL patients.
Objectives
In the present study we introduce serum adenosine deaminase as a diagnostic marker in CLL.
Materials and Methods
Blood samples were collected from B-CLL and healthy subjects. White blood cell, red blood cell and platelet count and blood Erythrocyte sedimentation rate was recorded and serum Beta-2-microglobulin, Lactate dehydrogenase and total ADA enzyme activity were determined.
Results
Serum ADA activity was significantly higher in patients group than that of controls. ADA had a significant and direct correlation with B2M, WBC, LDH and ESR. However, there was not any relation between ADA and the stages of disease. Diagnostic cut-off, sensitivity and specificity of the serum ADA test were 27.97 U/L, 91% and 94%, respectively.
Conclusions
A higher ADA activity in patients group and its correlation with CLL markers were seen in our study. High diagnostic value of serum ADA in our study suggests that it might be considered as a useful screening tool among the other markers in CLL.
